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Background: Many prostate cancers demonstrate an increased expression of growth factor receptors such as
vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) which
have been correlated with increased resistance to radiotherapy and poor prognosis in other tumors. Therefore,
response to radiation could potentially be improved by using inhibitors of these abnormally activated pathways.
We have investigated the radiosensitizing effects of sunitinib, a potent, multi-tyrosine kinase inhibitor of the VEGFR
and PDGFR receptors, on human prostate cancer cells.
Methods: The radiosensitizing effects of sunitinib were assessed on human prostate cancer cell lines DU145, PC3
and LNCaP by clonogenic assay. Sunitinib’s ability to inhibit the activities of its key targets was determined by
immunoblot analysis. The radiosensitizing effects of sunitinib in vivo were tested on human tumor xenografts
growing in nude mice where response was assessed by tumor growth delay.
Results: Clonogenic survival curve assays for both DU145 and PC3 cells showed that the surviving fraction at 2 Gy
was reduced from 0.70 and 0.52 in controls to 0.44 and 0.38, respectively, by a 24 hr pretreatment with 100 nM
sunitinib. LNCaP cells were not radiosensitized by sunitinib. Dose dependent decreases in VEGFR and PDGFR
activation were also observed following sunitinib in both DU145 and PC3 cells. We assessed the ability of sunitinib
to radiosensitize PC3 xenograft tumors growing in the hind limb of nude mice. Sunitinib given concurrently with
radiation did not prolong tumor growth delay. However, when animals were treated with sunitinib commencing
the day after fractionated radiation was complete, tumor growth delay was enhanced compared to radiation alone.
Conclusions: We conclude, based on the in vivo results, that sunitinib and radiation do not interact directly to
radiosensitize the PC3 tumor cells in vivo as they did in vitro. The fact that tumor growth delay was enhanced when
sunitinib was given after radiotherapy was completed suggests that sunitinib may be acting on the irradiated
tumor stroma and suppressing its ability to sustain regrowth of the irradiated tumor. Based on these preclinical
findings, we suggest that the combination of sunitinib and radiation for the treatment of prostate cancer deserves
further development.
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External beam radiotherapy has been used to treat pros-
tate cancers for more than five decades [1]; however,
continued improvement in the use of this modality is
warranted. The response of cancer cells to ionizing radi-
ation may be modified by various strategies to improve
antitumor effects. It is now understood that the expres-
sion of growth factor receptors such as vascular endo-
thelial growth factor receptor (VEGFR) and platelet
derived growth factor receptor (PDGF) may cause the
increased resistance to the damaging effects of radiation
[2]. VEGFR and PDGFR expression correlates with ves-
sel density and poor prognosis in various tumors that
exhibit resistance to cancer therapy. Although radiation
enhances the expression of both VEGFR and PDGFR,
combination studies using dual VEGFR/PDGFR inhibi-
tors in conjunction with radiation, have demonstrated a
marked enhancement of the antitumor effects [3,4].
Based on our expanding knowledge of signal transduc-
tion pathways in tumors, it is possible that the efficacy
of radiotherapy could be improved by including agents
that target VEGFR and PDGFR.
Sunitinib, a potent inhibitor of several tyrosine kinase
receptors, has demonstrated both antitumor and anti-
angiogenic activity. Preclinical biochemical and cellular
assay studies tested its activity against different kinases
and proved it to be a potent inhibitor of all three mem-
bers of the VEGFR family, both PDGFR β and β, C-KIT,
and Fms-like tyrosine kinase-3 (FLT3) [5].
Studies using human (H460, A431) derived xenograft
tumors showed that a dose of 20–80 mg/kg/day of suni-
tinib resulted in tumor growth inhibition of 11-93% [6].
Human glioblastoma xenografts, treated with sunitinib
at plasma concentrations of 50-100 ng/ml, exhibited a
reduction in density and an increase in apoptosis in
micro-vessels [7]. Inhibition of PDGFR phosphorylation
and reduction in neovascularization have also been
observed [8,9]. Previous reports also described sunitinib
as an effective means to enhance the cytotoxic effects of
ionizing radiation. Concurrent treatment attenuated the
ERK and AKT pathways in pancreatic adenocarcinoma
xenografts [10]. Furthermore, sunitinib reduced clono-
genic survival in irradiated endothelial cells when com-
pared to radiation alone. The synergy observed in vitro
was confirmed under in vivo conditions using a hind
limb xenografts tumor model, which resulted in a sig-
nificant delay in tumor growth [11].
In the present study, this multi-tyrosine kinase inhibi-
tor was tested on prostate cancer cells in order to evalu-
ate its effectiveness at enhancing the antitumor effects of
radiation. The results indicate that sunitinib enhances
the radioresponse of human prostate cancer cells
in vitro and in vivo but that the mechanism of this en-
hancement may be different in these two model systems.Methods
Cell culture
The following three human prostate cell lines were
obtained from American Type Culture Collection and eval-
uated for radiosensitization: PC3, DU145 and LNCaP. Both
PC3 and DU145 cells were routinely maintained in RPMI
1640 medium while LNCaP cells were cultured in DMEM/
F12 medium. All media was supplemented with 10%
fetal bovine serum, 2 mM L-Glutamine and 100-units/ml
penicillin-streptomycin, and all three lines were grown in
an exponential growth phase at 37°C and 5% CO2 in a hu-
midified atmosphere.
Chemicals
Sunitinib was obtained from Pfizer Inc. in a powder
form and aliquots were dissolved in DMSO and stored
at −80°C.
Western blot analysis
Cells were harvested two hours post-irradiation by tryp-
sinization and centrifuged at 4°C for 10 minutes at
1100 rpm. Subsequent pellets were then resuspended in
ice-cold lysis buffer (50 mM Hepes, pH 7.9, 0.4 mM
NaCl, 1% NP-40, 1 mM EDTA, 2 μg/ml leupeptin, 2 M
aprotinin, 5 M benzamidine and 0.5 mM/L phenyl-
methylsulfonyl fluoride). The protein concentration of each
sample was determined by the DC protein assay (Bio-Rad
laboratories, Hercules, LA), using a 96-well plate in a Per-
kin Elmer Wallac Victor 1420 plate reader. Equal amounts
of protein were separated by 8-15% SDS–PAGE, trans-
ferred to polyvinylide difluoride membranes (Millipore,
Billerica, MA) and blocked for 90 minutes in 5% nonfat
dry milk TBS-T (0.05% v/v). Membranes were incubated
overnight at 4°C in primary antibody including both total
and phosphorylated forms of VEGFR, PDGFR, C-KIT,
FLT3, AKT and ERK at a 1:1000 dilution in 5% BSA. Blots
were washed three times and incubated with a horseradish
peroxidase-conjugated secondary antibody (1:350 dilution;
Amersham Biosciences) for 90 minutes. Blots were visua-
lized by chemiluminescence with ECL-plus detection re-
agent (Amersham Biosciences, Arlington Heights, IL)
according to manufacturer’s directions, on a Typhoon 9400
scanner (Amersham Biosciences, Piscataway, NJ).
Clonogenic survival assay
Cells were seeded in T25 flasks and treated with suniti-
nib/DMSO at the indicated concentrations. Following
various incubation periods, non-confluent cultures of
LNCaP, PC3 and DU145 cells were irradiated using a
137Cs source. Cells were trypsinized, counted, and
known numbers were re-plated in 60 mm dishes in trip-
licate and returned to the incubator. For DU145 and
PC3, colonies were stained with crystal violet 12 days
later with a longer incubation of 18 days allowed for
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were counted and the percentage plating efficiency and
surviving fraction for a given radiation dose were calcu-
lated based on the survival of non-irradiated cells treated
with either drug or vehicle alone.
Mice
Male nude (nu/nu) mice were used for the in vivo stud-
ies. They were bred in the Experimental Radiation On-
cology specific-pathogen free barrier mouse facility and
were 3–4 months of age at the start of the experiments.
Mice were housed 3–5 per cage, exposed to 12-hour
light dark cycles, and given free access to sterilized pel-
leted food (Prolab Animal Diet, Purina Mills Inc., St.
Louis, MO) and sterilized water. Animals were main-
tained in an Association for Assessment and Accredit-
ation of Laboratory Animal Care approved facility, and
in accordance with current regulations of the United
States Department of Agriculture and Department of
Health and Human Services. The experimental protocol
was approved by, and in accordance with, institutional
guidelines established by the Institutional Animal Care
and Use Committee.
Tumor implantation and antitumor efficacy studies
Solitary tumors were produced by inoculation of 1 x 106
PC3 cells into the right hind leg of mice. When tumors
grew to 7 mm in diameter (range 6.8-7.3 mm), mice were
randomized into groups and treatment initiated as follows:
1) vehicle only, 2) sunitinib only, 3) local tumor irradiation
(XRT), 4) a combination of sunitinib and XRT or 5) no
treatment (control). Groups consisted of 4 to 8 animals
each. Sunitinib was given at a dose of 1.2 or 1.3 mg/mouse
daily for 5 days by oral gavage using 2 different protocols:
either 1 h before each dose of radiation or starting 24 h fol-
lowing the last dose of radiation. Radiation was delivered
in 5 daily fractions of 1 or 3 Gy. Tumor bearing mice were
locally irradiated without anesthesia using a small animal
irradiator (Atomic Energy of Canada, Ottawa, Canada)
consisting of parallel opposed 137 Cs sources, at a dose rate
of 5 Gy/min.
Tumor growth delay was the endpoint used to deter-
mine antitumor efficacy of the treatments. To obtain
tumor growth curves, three mutually orthogonal dia-
meters of tumors were measured 2–3 times/week with a
vernier caliper, and the mean values were calculated.
Tumor growth delay plots were generated depicting
average tumor diameter as a function of days after initial
treatment. Tumor bearing mice were euthanized by CO2
inhalation when tumors grew to 14–15 mm diameter.
Regression and subsequent regrowth of tumors was
expressed as the time in days for tumors in the treated
groups to grow from 7 mm to 12 mm in diameter minus
the time in days for tumors in the control group toreach the same size. This was termed absolute growth
delay (AGD).Immunofluorescence staining
For detection of radiation-induced DNA double strand
breaks (DSBs) by γH2AX foci, we used a procedure
reported previously [12]. Briefly, cells were grown over-
night on cover slips in 35 mm dishes and treated for
varying time periods in sunitinib. Dishes were irradiated
with 2 Gy using a 137Cs source. At varying time points,
medium was aspirated and cells were washed in PBS (Ca
and Mg free) for 5 minutes. Cells were then fixed with
1% paraformaldehyde for 10 minutes followed by sub-
mersion in 70% ethanol for another 10 minutes. Follow-
ing fixation, cells were incubated in 0.1% NP-40 (made
in PBS) for 20 minutes before two five-minute washes
and placed in 5% BSA (in PBS) blocking buffer for
30 minutes. Following blocking, primary antibody for
γH2AX was prepared in 5% BSA-PBS at a 1:300 dilution.
Incubation lasted 2 hours with gentle shaking at room
temperature. Cells were subsequently washed four times
at 10 minutes each in PBS before incubation for 30 min-
utes in FITC- labeled secondary antibody at a dilution of
1:300 (γH2AX) in 5% BSA-PBS. Incubation was followed
by another four washes at 10 minutes each in PBS. Cells
were subjected to DAPI (44’, 6-diamidino-2-phenylindole
1 ug/ml) in PBS for 5 minutes. Following the fourth and
final wash cover slips were removed from the dishes and
placed onto antifade solution mounted slides. Slides
were sealed and examined using a Leica fluorescence
microscope. The number of foci was manually counted
in at least 40 cells per sample. Each independent experi-
ment was repeated 3 times.Statistical analysis
The averages of at least three independent experiments
were used in each independent study. Data was analyzed
using the paired t-test and described as +/− standard error
(SE). A difference of p<0.05 was deemed as significant.Results
RTK expression in three prostate cell lines
As stated, sunitinib has been shown to be a potent inhibi-
tor of certain receptor tyrosine kinases (RTK’s) including
VEGFR2, PDGFR-β, c-KIT and FLT3. We determined the
expression levels of these receptors in all three prostate cell
lines by western blot analyses (Figure 1). DU145 cells were
found to be positive for VEGFR2, PDGFR- and C-KIT.
PC3 cells were found to be only positive for PDGFR-, while
LNCaPs proved to be negative for all four receptors. FLT3
was not expressed by any of the three cell lines.
Actin
Expression of Receptor Tyrosine Kinases
Figure 1 Expression of RTK’s detected by western blot analysis.
Three prostate cell lines PC3, LNCaPs and DU145 were assessed for
the presence of RTKs, shown to be targets of sunitinib (c-KIT,
VEGFR-2, PDGFR- and FLT3). DU145 was found to be positive for all
except for FLT3. PDGFR- was the only RTK found to be expressed in
PC3 cells while LNCaPs were found to be negative for all four.
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We next tested whether sunitinib inhibited the activa-
tion of these targets in the cell lines under inves-
tigation. Decreased levels of p-PDGFR-β, p-VEGFR2 and
p-C-KIT were observed in un-irradiated DU145 cells fol-
lowing a 24 hour pretreatment with both 100 and 250
nM sunitinib (Figure 2A). Decreased levels of p-PDGFR-
β were also observed in un-irradiated PC3 cells following
a 24-hr pretreatment with both 100 and 250 nM suniti-
nib (Figure 2B). In irradiated DU145 samples, 100 nMWestern blot analysis showing effects of Sunitinib
Figure 2 Western blot analysis of the effects of sunitinib, with
or without irradiation, on three of its trans-membrane receptor
targets. Both total and phosphorylated forms of PDGFR-β, VEGFR2,
and C-KIT were detected by western blot analysis. Both DU145 (A)
and PC3 (B) cells were treated with sunitinib (40, 100, 250 nM for
24 hours) and harvested for western blot analysis 2 h after
irradiation. β-Actin was used as a loading control.sunitinib reduced the phosphorylation of both p-C-KIT
and p-PDGFR-β, below the level of both control and ra-
diation alone. Sunitinib although effective at reducing
the expression of p-VEGFR2 at a concentration of both
100 and 250 nM, did not appear to reduce the expres-
sion when combined with 5 Gy (Figure 2A). Both 100
and 250 nM of sunitinib in combination with 5 Gy was
found to be effective at reducing the expression of
p-PDGFR-β when compared to control and radiation
alone in the PC3 cell line (Figure 2B).
Radiosensitization determined by clonogenic survival
assays
We assessed the radiation enhancing effects of sunitinib
by use of clonogenic survival assays. For the DU145
cells, following a 24-hour incubation period, the survival
fraction at 2 Gy (SF2) was reduced from 0.70 in the con-
trol cells to 0.44 in 100 nM sunitinib-treated cells
(Figure 3A). The radiosensitizing effect of sunitinib on
DU145 cells was not further increased by using doses
higher than 100 nM drug (data not shown). For PC3
cells (Figure 3B), the optimum dose range was found to
be between 100 nM and 250 nM; doses higher than 250
nM had no further radiosensitizing effects. Using a
24-hour pretreatment with 250 nM of sunitinib the SF2
was reduced from 0.52 in the control to 0.38 in the trea-
ted sample. Only a slight but insignificant difference was
observed in respect to varying incubation periods for the
sunitinib treatments (data not shown). Sunitinib did not
exhibit a radiosensitizing effect on the LNCaP cell line
(Figure 3C), correlating with the lack of targets in these
cells as was shown in Figure 1. In addition to calculating
SF2 values, we also calculated the dose enhancement
factors (DEF), that is, the ratio of doses required to re-
duce survival to 10%. The DEF values for DU145 and
PC3 were both 1.1 whereas the DEF value for the LnCaP
cells was 1.0. At the nM concentrations used in these
experiments, sunitinib alone did not lower the plating
efficiencies for the cell lines examined.
Inhibition of downstream signaling
Radiation-induced phosphorylation of both ERK and
AKT was observed in DU145 cells (Figure 4A) but not
in PC3 cells (Figure 4B). With respect to p-ERK, suniti-
nib, at all 3 concentrations tested, suppressed p-ERK ac-
tivation in the sunitinib + radiation samples compared
to the 5 Gy only samples in both cell lines. With respect
to p-AKT, expression was reduced in the sunitinib trea-
ted samples for the DU145 cells but this suppression
was not maintained in the sunitinib + radiation samples.
Immunofluorescence staining for γH2AX foci
Cells were harvested at given time points post radiation





















































Figure 3 Assessment of radiosensitization by sunitinib using
clonogenic survival assays. Sunitinib radiosensitized both DU145
(A) and PC3 (B) cells using concentrations of 100 nM for the DU145
cells and 250 nM for the PC3 cells. LnCap (C) cells were not
radiosensitized with 250 nM. Cells were treated with sunitinib for
24 hrs and assessed for radiosensitization by clonogenic cell survival
immediately after irradiation. Each data point represents the average
of three independent experiments each plated in triplicate.
* indicates p< 0.05.
A
B
Western blot analysis on cells treated with Sunitinib
Figure 4 The effects of sunitinib on downstream signals. Both
DU145 (A) and PC3 (B) cells were treated with sunitinib (40, 100,
250 nM) and harvested for western blot analysis 2 hours after
irradiation (5 Gy). Cells were assessed for the effect of sunitinib on
two key signaling proteins, ERK and AKT; both of which are involved
in the radiation response and lie downstream of all three RTK
targets, p-PDGFR-β, p-VEGFR2, and p-C-KIT. Actin was used as a
loading control.
Figure 5 Immunofluorescence detection of γH2AX stained DNA
repair foci. DU145 cells were treated for 24 hrs with 100 nM
sunitinib and irradiated with 2 Gy. Cells were harvested at the
indicated times and stained for γH2AX. Foci per cell were counted in
40 cells per sample. Error bars represent standard error.
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detected on the basis of γH2AX foci. Radiation-induced
γH2AX foci were detected in DU145 cells 30 min fol-
lowing 2 Gy irradiation (Figure 5) and the level of foci
decreased with time over the next 6 hrs indicating repairof the DSBs. Sunitinib treatment, however, did not alter
either the induction or subsequent disappearance of foci
at any time examined suggesting that sunitinib does not
affect the repair of radiation-induced DSBs. An identical
experiment was conducted using PC3 cells and, similar
to the case for DU145 cells, sunitinib did not alter the
kinetics of γH2AX foci induction or disappearance in
these cells either (data not shown).
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We assessed the ability of sunitinib to radiosensitize
PC3 xenograft tumors growing in the hind limb of
nude mice. Radiation doses were delivered to 7 mm-
diameter tumors in 5 daily fractions of 1 or 3 Gy. In
the first set of experiments, sunitinib was given by
gavage as 1.2 mg/mouse for 5 days concurrent with
fractionated irradiation or following the completion of
radiation. The animals were followed for several weeks
after treatment and tumor growth curves were gener-
ated for the different treatment groups (Figure 6A).
The results show that sunitinib by itself produced a
slight but not statistically significant growth delay
compared to untreated controls. Fifty days after initial
treatment, the average tumor size was 14.8 mm (±2.4)
for untreated controls, 15.7 mm (±1.5) for mice trea-
ted with vehicle alone and 13.1 mm (±2.7) for mice
treated with sunitinib alone. Radiation, by itself, pro-
duced significant tumor growth delay; average tumor
size on day 50 was only 7.8 mm (±1.1) (p = 0.01).
Mice with tumors that received irradiation were fol-
lowed for 64 days following initiation of treatment.
Tumors in irradiated mice at 64 days were 9.3 mm
(±1.3) after radiation only, 11.0 mm (±0.5) after suniti-
nib given concurrent with radiotherapy and 7.1 mm
(±1.0) when sunitinib was delivered post radiation
treatment. Thus, sunitinib given concurrently with ra-
diation did not prolong tumor growth delay, while
sunitinib treatment initiated after the completion of
fractionated radiation appeared to enhance tumor
growth delay.Days After Initial Treatment
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Sunitinib (1.2mg/mouse) x 5 days
XRT only (3Gy x 5 days)
XRT + sunitinib 1h before XRT x 5 days
XRT x 5 days + sunitinib post XRT x 5 days
A 
Figure 6 Tumor growth delay curves for PC3 xenografts treated with
generated by inoculation of PC3 cells into legs of nude mice and treatmen
vehicle only for 5 days, sunitinib (1.2 mg/mouse) only for 5 days, local tum
each radiation dose, sunitinib for 5 days beginning 1 day after completion
sunitinib (1.3 mg/mouse) only for 5 days, local tumor radiation only (1 Gy d
doses, sunitinib for 5 days beginning 1 day after completion of 5 radiation
6–8 mice; bars, SE.We performed a second in vivo study using a lower ra-
diation dose in order to assess the time for tumors to
grow from 7 mm to 12 mm, AGD. In this case, we
increased the dose of sunitinib to 1.3 mg/mouse for
5 days and decreased the radiation dose to 1 Gy per
fraction for 5 days (Figure 6B). All treatments prolonged
the time for PC3 tumors to grow to 12 mm when com-
pared to untreated controls (AGD): sunitinib alone
delayed tumor growth by 19.1 (±5.3) days and radiation
alone by 19.4 (± 9.0) days. Administration of sunitinib
1 h before each dose of radiation did not augment radi-
ation induced tumor growth delay (AGD 20.7 ± 5.6 days);
however sunitinib treatment initiated 24 h following the
last dose of radiation did provide additional growth delay
(AGD 38.0 ± 8.3 days) but this increase in AGD did not
reach statistical significance when compared to radiation
alone (p = 0.15). However, this second study confirmed
the initial finding that the sequential treatment schedule
with sunitinib administration following the completion
of radiation treatment resulted in superior anti-tumor
efficacy.
Discussion
Previous reports have shown that interruption of VEGFR
or PDGFR signaling can enhance the damaging effects
of ionizing radiation [3]. For example, targeted therapy
using cediranib, a small molecule VEGFR-inhibitor used
in junction with radiotherapy, synergistically enhanced
the growth delay of calu-6 lung xenografts and was asso-
ciated with increased levels of apoptosis and necrosis in
histological samples [13]. Cuneo et al. [10] demonstratedDays After Initial Treatment



















Vehicle only x 5 days
Sunitinib (1.3mg/mouse) x 5 days
XRT only (1Gy x 5 days)
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B 
the combination of sunitinib and radiation. Tumors were
ts initiated when tumors grew to 7 mm. Panel A: untreated control,
or radiation only (3 Gy daily for 5 days), sunitinib for 5 days 1 h before
of 5 radiation doses. Panel B: untreated control, vehicle only for 5 days,
aily for 5 days), sunitinib for 5 days 1 h before each of 5 radiation
doses. Each data point represents average tumor diameter for
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for the treatment of human pancreatic adenocarcinomas.
Their results revealed that sunitinib or radiation when
used alone delayed tumor growth, however when com-
bined, the delay was significantly enhanced. Similar find-
ings were reported for Lewis carcinomas treated in vivo
with the combination of sunitinib and radiation [11].
Thus with prior reports illustrating the effectiveness of
the combination of sunitinib and radiation on both cell
lines and xenograft tumors, derived from a variety of
human cancers, we investigated whether it would radio-
sensitize three prostate cell lines; the hormone inde-
pendent DU145 and PC3 and hormone dependent
androgen receptor expressing LNCaPs. This was of
interest because the radioresistance of prostate cancer
cells potentially limits the outcome of radiotherapy for
this disease and inhibitors directed at the mechanisms of
resistance might be of benefit.
Western blot analysis (Figure 1) showed that DU145
and PC3 cells express one or more of sunitinib’s cellular
targets, i.e. VEGFR2, PDGFR- and c-Kit. Based on this,
we postulated that sunitinib would radiosensitize these
two cell lines but perhaps not radiosensitize the LNCaP
cell line, found to express none of the given targets. This
indeed turned out to be the case when sunitinib radio-
sensitization was assessed by clonogenic assay (Figure 3);
DU145 and PC3 cells were modestly radiosensitized and
LnCaP cells were not. However, in spite of the modest
radiosensitization seen using sunitinib on DU145 and
PC3 cells, the reduction in SF2 values observed would
be predicted to have clinical impact in a fractioned treat-
ment protocol in prostate cancer patients.
In spite of growing interest in combining novel tyro-
sine kinase inhibitors (TKIs) with conventional techni-
ques such as radiotherapy, the molecular mechanisms
by which TKIs elicit their sensitizing effects remain to
be elucidated [14]. However, generally, it appears that
many if not most TKIs inhibit signaling downstream
of growth factor receptors mediated by the PI3K-AKT
and Ras-Raf-MEK-ERK pathways [15,16]. Activation of
both the ERK and AKT pathways are a frequent event
in prostate cancers and a strong association between
the expression of these kinases and poor prognosis is
often observed [17,18]. Thus, we tested whether suniti-
nib suppressed p-AKT and/or p-ERK, 2 appropriate
downstream elements of the signaling pathways under
investigation. The results showed that sunitinib sup-
pressed p-ERK in un-irradiated and irradiated DU145
and PC3 cells suggesting that radioresistance in these
cells lines is mediated through the Ras-Raf-MEK-ERK
pathway. This is consistent with numerous reports in
the literature illustrating the importance of this path-
way in governing radiation response in tumor cells
[19].Perhaps the most important mechanism for dictating
the cytotoxicity of ionizing radiation involves the repair
of radiation-induced DNA double strand breaks (DSBs)
[20]. Repair of these lesions critically determines the de-
gree of cell killing by radiation. Induction and repair of
radiation-induced DSBs is commonly followed using the
detection of γH2AX foci [21]. This assay is very sensitive
and we have used it previously to demonstrate that the
radiosensitizing action of other molecularly-targeted
agents involves an inhibition of DSB repair detected on
the basis of a prolongation of γH2AX foci in the agent
plus radiation samples compared to radiation alone con-
trols [12]. In the present study, however, we were unable
to detect any prolongation of γH2AX foci by sunitinib
(Figure 5) suggesting that sunitinib does not interfere
with the repair of radiation-induced DSBs. This may not
be too surprising since the degree of radiosensitization
produced by sunitinib here is small compared to what
was observed in our previous studies using other mo-
lecularly targeted agents. Thus, it is conceivable that
sunitinib suppresses DSB repair to a small degree that is
undetectable by this assay or that sunitinib radiosensi-
tizes by some other mechanism.
Based on the experiments conducted in vitro, we
hypothesized that daily sunitinib treatments concurrent
with daily fractionated radiation would enhance tumor
growth delay compared to radiation alone. However,
sunitinib given concurrently with radiation did not pro-
long tumor growth delay. Conversely, when animals
were treated with sunitinib commencing the day after
fractionated radiation was complete, tumor growth delay
was enhanced. We conclude that, at least in this treat-
ment protocol and tumor model, sunitinib and radiation
do not interact directly to radiosensitize the PC3 tumor
cells in vivo as they did in vitro or that the modest de-
gree of radiosensitization seen in vitro cannot be
observed in the in vivo model. Alternatively, the anti-
angiogenic activity of sunitinib may increase tumor
hypoxia when administered prior to radiation thereby
decreasing radiosensitivity and offsetting any radiosensi-
tizing effect of the drug [22]. This possibility is sup-
ported by previous reports showing that sunitinib and
other anti-angiogenic agents may enhance tumor blood
vessel distruction during fractionated irradiation [11,23].
The fact that tumor growth delay was enhanced when
sunitinib was given after radiotherapy was completed
suggests that sunitinib may be acting on the irradiated
tumor stroma and suppressing its ability to sustain re-
growth of the irradiated tumor. This latter effect is con-
sistent with previous reports illustrating enhanced
tumor control when anti-angiogenic agents are applied
after the completion of radiotherapy [11]. For example,
Zips et al. reported that the adjuvant application of
PTK787/ZK222584 preferentially retarded tumor growth
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Similar findings have been reported for other anti-
angiogenic agents including bevacizumab, ZD6474 and
sunitinib [11,23,27].
Our results demonstrate the effectiveness of sunitinib
when combined with radiation for enhancing the radio-
sensitivity of androgen independent prostate cancer cells
when treated in vitro. Although a mechanism mediating
this response was not isolated, further studies into sig-
naling functions downstream of sunitinib’s targeted
growth factor receptors may ultimately provide greater
insights. In the in vivo study, enhancement of tumor
growth delay was not observed when sunitinib was given
concurrently with fractionated radiation. However, tunor
growth delay was enhanced when sunitinib treatment
was initiated after the completion of fractionated radi-
ation suggesting that sunitinib suppresses the ability of
the tumor stroma to sustain regrowth of the irradiated
tumor. Castrate-resistant clones can be a dilemma for
radiation since the best outcomes depend on combin-
ation therapy with androgen deprivation to decrease
tumor bulk locally and prevent or delay metastasis. The
data submitted here and other reports in the literature
suggest that the combination of TKIs such as sunitinib
with radiation offers a promising approach. However,
the effectiveness of such combinations may critically de-
pend on appropriate scheduling of the agents.Conclusion
Sunitinib at doses of 100 nM and 250 nM modestly
enhanced the radiosensitivity of DU145 and PC3 hor-
mone-independent, human prostate cancer cell lines, re-
spectively but did not sensitize the androgen-dependent
cell line LNCaP. Sunitinib does not appear to mediate
its radio-sensitizing effect via interruption of DNA re-
pair. The fact that tumor growth delay was only
enhanced when sunitinib was given after radiotherapy
was completed suggests that sunitinib may be acting on
the irradiated tumor stroma and suppressing its ability
to sustain regrowth of the irradiated tumor rather than
by radiosensitizing during radiation. Thus, based on the
in vivo results, we believe that the combination of suniti-
nib and radiation offers a promising approach for treat-
ing human prostate cancer.Competing interests
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